Open Access

Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis

Respiratory Research20067:87

DOI: 10.1186/1465-9921-7-87

Received: 27 January 2006

Accepted: 09 June 2006

Published: 09 June 2006

Abstract

Background

L-arginine is the common substrate for nitric oxide synthases and arginases. Increased arginase levels in the blood of patients with cystic fibrosis may result in L-arginine deficiency and thereby contribute to low airway nitric oxide formation and impaired pulmonary function.

Methods

Plasma amino acid and arginase levels were studied in ten patients with cystic fibrosis before and after 14 days of antibiotic treatment for pulmonary exacerbation. Patients were compared to ten healthy non-smoking controls.

Results

Systemic arginase levels measured by ELISA were significantly increased in cystic fibrosis with exacerbation compared to controls (17.3 ± 12.0 vs. 4.3 ± 3.4 ng/ml, p < 0.02). Arginase levels normalized with antibiotic treatment. Plasma L-arginine was significantly reduced before (p < 0.05) but not after treatment. In contrast, L-ornithine, proline, and glutamic acid, all downstream products of arginase activity, were normal before, but significantly increased after antibiotic therapy. Bioavailability of L-arginine was significantly reduced in cystic fibrosis before and after exacerbation (p < 0.05, respectively).

Conclusion

These observations provide further evidence for a disturbed balance between the L-arginine metabolic pathways in cystic fibrosis.

Background

Nitric oxide (NO) is a messenger molecule that is involved in a variety of biological and physiological processes in the lung. Constitutive endogenous formation of NO in airways is thought to play a role in neurotransmission, smooth muscle relaxation and bronchodilation. [1] Airway NO formation by NO synthases (NOSs) can be increased in response to inflammatory mediators predominantly through induction of the calcium-independent isoform NOS2. [1] Despite the inflammatory nature of lung disease in cystic fibrosis (CF), fractional exhaled NO (FENO), as well as concentrations of the bioactive NO-metabolites S-nitrosothiols (SNOs) in airway fluids are decreased in CF patients. [24] While the reasons for impaired NO formation remain incompletely understood, there is accumulating evidence that low airway NO contributes to lung pathophysiology in CF. [59]

Enzymatic NO formation from NOSs requires the semi-essential amino acid L-arginine as substrate. L-arginine is also metabolized by an enzyme of the urea cycle named arginase which exists in type I and type II isoforms. While arginase II is located mitochondrial, arginase I is a cytoplasmatic enzyme. Arginase can limit NO formation through increased consumption of the common substrate. [1012] It was recently shown that arginase activity is increased in sputum of patients with CF. [9] Evidence for increased systemic arginase activity in CF came from a study showing that oral supplementation of L-arginine in a single dose of 200 mg/kg body weight resulted in a significantly higher increase of L-ornithine, the product of arginase activity, in plasma of CF patients compared to healthy controls. [13] These data suggest that the consumption of L-arginine by arginase could be increased in CF, possibly resulting in reduced availability of L-arginine for NO synthesis. To address this question, we measured plasma amino acid levels and arginase concentrations in patients with CF before and after antibiotic treatment for pulmonary exacerbations.

Methods

Study cohort and protocol

10 CF patients (3 females) aged 16 to 39 years with a mean (± SD) age of 21.9 (± 6.2) years were included in this study. The diagnosis of CF had been confirmed in all patients by repeated sweat tests with chloride concentrations exceeding 60 mmol/L and by CFTR gene mutation analysis. Exclusion criteria were g-tube feeding, allergic bronchopulmonary aspergillosis or B. cepacia infection. Patients studied were admitted to hospital for intravenous antibiotic treatment of a pulmonary exacerbation. Blood was drawn into two 2.7 ml EDTA containing tubes for plasma amino acid (n = 10) and arginase (n = 7) measurements on the morning after admission and after 14 days of antibiotic treatment under fasting conditions in the morning prior to breakfast, respectively. Pulmonary function tests by spirometry were performed on the same day in each patient but one, who was unable to perform spirometry. Mean forced vital capacity (FVC) at admission was 54.1 (± 22.7) % and FEV1 was 32.4 (± 10.6) % of predicted values, respectively. Mean BMI of the patients was 18.5 (± 2.2). Sputum microbiology revealed P. aeruginosa in 8 patients, Acinetobacter baumanii in 1 and Stenotrophomonas plus Staph. aureus in one patient. Patients were treated with ceftazidime (n = 5) or meropenem (n = 5) plus an aminoglycoside respectively. One patient received oral steroids on three days during treatment, two additional patients were on long term treatment with inhaled budesonide.

Patients were compared to 10 (3 females) non-smoking, healthy controls that were 23 to 28 years (24.4 ± 2.1 years) of age. In controls blood was also drawn into two 2.7 ml EDTA containing tubes in the morning under fasting conditions. Written informed consent was obtained from each CF patient, and/or their parents, and all healthy controls, respectively. The study was approved by the institutional review board of the University of Duisburg-Essen.

Plasma amino acids measurements

Amino acids were determined by ion exchange chromatography on an amino acid analyzer LC 3000 (Eppendorf, Hamburg, Germany) according to the manufacturer's specifications. Plasma samples were deproteinized within 30 minutes after collection.

Arginase ELISA

Plasma levels of arginase I (liver type) were measured using a commercially available enzyme-linked immonosorbent assay (ELISA) kit (BioVendor Laboratory Medicine, Inc. Brno, Czech Republic). Plasma samples for the arginase ELISA were centrifuged at 1000 g for 10 min immediately after they were obtained. Clear supernatant was kept at -80C before analyzed.

Statistics

Data were expressed as mean ± standard deviation (SD). Kolmogorov-Smirnov test revealed normal distribution of all values in the groups. Comparisons within groups (pre vs. post treatment) were therefore made by paired t-test and inter-group comparisons were done by unpaired t-test. A p value below 0.05 was considered statistically significant. PC-Statistik v2.11 (TopSoft Hannover, Germany) was used for statistical analysis.

Results

Amino acid levels

Significantly reduced plasma concentrations were found for 9 out of 20 amino acids tested in CF patients admitted with pulmonary exacerbations. With the exception of histidine none of the amino acid levels were subnormal after 14 days of antibiotic therapy. Glycine as well as the downstream products of arginase activity, i.e. L-ornithine, proline, and glutamic acid were not reduced at admission but were significantly increased after antibiotic therapy when compared to controls, respectively (Table 1) (Figure 1).
Figure 1

Plasma amino acids. Plasma concentrations of L-arginine (A), L-ornithine (B), proline (C), and glutamic acid (D) in cystic fibrosis patients (CF) before (baseline) and after 14 days of antibiotic treatment as well as controls. Results are plotted as means ± SD. Asterisk indicates significant (p < 0.05) difference to controls.

Table 1

Plasma amino acid levels (μM) in controls and CF patients before and after 14 days of i.v. antibiotic treatment for pulmonary exacerbation

  

CF patients (n = 10)

 

Controls (n = 10)

before (% control)

after (% control)

P-value

L-arginine

67.7 ± 19.0

48.1 ± 19.9 (71) *

68.9 ± 19.5 (102)

0.02

L-ornithine

45.7 ± 13.8

56.6 ± 34.0 (124)

65.9 ± 15.5 (144)†

NS

L-citrulline

27.5 ± 8.8

28.3 ± 5.5 (103)

33.4 ± 5.8 (121)

NS

Threonine

128.1 ± 40.0

87.2 ± 30.7 (68) *

129.7 ± 50.4 (101)

0.01

Serine

97.7 ± 30.0

92.0 ± 26.3 (94)

92.9 ± 17.2 (95)

NS

Asparagine

52.5 ± 14.5

37.3 ± 12.4 (71) *

40.0 ± 11.0 (76)

NS

Glutamic Acid

18.6 ± 7.1

69.7 ± 40.7 (375) †

65.7 ± 52.5 (353)*

NS

Proline

170.3 ± 31.8

165.4 ± 43.2 (97)

216.8 ± 57.5 (127)*

NS

Glycine

205.1 ± 52.9

241.8 ± 100.6 (118)

323.5 ± 69.1 (158)†

0.02

Alanine

328.5 ± 73.6

243.1 ± 90.8 (74) *

355.3 ± 139.6 (108)

NS

Valine

203.0 ± 25.0

169.7 ± 32.1 (84) *

176.1 ± 39.6 (87)

NS

Cysteine

55.3 ± 15.6

30.1 ± 9.0 (54) †

42.4 ± 13.7 (77)

0.004

Methionine

24.9 ± 4.8

19.2 ± 5.2 (77) *

21.0 ± 5.6 (84)

NS

Isoleucine

57.6 ± 10.9

52.3 ± 18.1 (91)

62.9 ± 12.9 (109)

NS

Leucine

111.3 ± 22.2

90.4 ± 25.1 (81)

96.1 ± 23.9 (86)

NS

Tyrosine

54.7 ± 9.8

45.7 ± 14.3 (84)

44.7 ± 11.3 (82)

NS

Phenylalanine

49.9 ± 6.8

47.7 ± 10.7 (96)

49.0 ± 10.3 (98)

NS

Histidine

83.7 ± 7.2

55.9 ± 17.7 (67) †

64.4 ± 17.6 (77)†

NS

Tryptophan

49.8 ± 9.5

30.7 ± 15.8 (62) †

46.6 ± 11.7 (94)

0.02

Lysine

144.7 ± 42.5

144.0 ± 40.5 (100)

183.8 ± 51.9 (127)

NS

Concentrations of amino acids are expressed in means ± SD. Symbols indicate significant differences of CF group to controls; *: p < 0.05, †: p ≤ 0.01. P-values shown are for comparison between CF groups before and after antibiotic treatment.

L-arginine plasma concentrations were decreased in CF patients with an exacerbation when compared to controls, with three patients having values of 13.6 μM, 21.2 μM, and 35.1 μM respectively, which is below published reference values (36–139 μM). [14] Plasma L-arginine significantly increased to normal values in CF during antibiotic therapy (Figure 1). The rate limiting factor for cellular uptake of L-arginine is the CAT transporter, which also transports L-ornithine and lysine. [15] The ratios of L-arginine/L-ornithine, as well L-arginine/L-ornithine + lysine, therefore, provide indices of relative L-arginine availability at any given plasma L-arginine concentration. Both these ratios were significantly reduced in the CF patients before and after treatment for pulmonary exacerbation (Figure 2).
Figure 2

L-arginine bioavailability. L-arginine bioavailability indices in CF patients before (baseline) and after 14 days of antibiotic treatment and in controls. Results are plotted as means ± SD. Asterisk indicates significant (p < 0.05) difference to controls.

Arginase concentrations

Plasma arginase concentrations in healthy controls were 4.3 ± 3.4 ng/ml. Arginase levels were significantly increased in CF patients with pulmonary exacerbation (17.3 ± 12.0 ng/ml, p < 0.02) and returned to normal values after 14 days of antibiotic therapy (2.4 ± 2.3 ng/ml) (Figure 3).
Figure 3

Arginase I in plasma. Arginase I plasma concentrations measured by ELISA in CF patients before (baseline) and after 14 days of antibiotic treatment and in controls. Results are plotted as means ± SD. Asterisk indicates significant (p < 0.05) difference to controls.

Discussion

In this study we found evidence for reduced systemic availability of L-arginine, the substrate for NOS, in CF patients. While increased arginase I and decreased L-arginine concentrations in plasma at the time of pulmonary exacerbation normalized with antibiotic treatment, the relative bioavailability of L-arginine remained significantly reduced in CF patients. This was associated with an amino acid profile consistent with increased arginase activity even after treatment for pulmonary exacerbation.

L-arginine is a semi-essential amino acid that is found in many comestible goods but can also be biosynthesized from citrulline (by argininosuccinate synthase and argininosuccinate lyase, the third and fourth enzymes of the urea cycle). L-arginine is essential for protein synthesis and a substrate for urea, polyamines, proline, L-glutamine, creatinine phospate, agmatine as well as enzymatic NO formation. Arginine is transported from blood into cells by cationic amino acid transporter (CAT) isoforms. The availability of L-arginine is one of the rate-limiting factors in cellular NO production. [10, 12] Therefore, L-arginine deficiency may, at least in part, account for the reduced NO formation seen in the CF airways.

A lack of NO formation is of relevance for CF pathophysiology since there is increasing evidence that decreased NO formation has a negative effect on defense against bacterial infections, and contributes to airway obstruction in CF. [2, 5, 7, 9, 1618] However, most actions of NOSs seem to be mediated by S-nitrosylated proteins and not by NO itself [19]. Depletion of S-nitrosothiols (SNOs) is thought to aggravate airway obstruction [2022], and SNO levels were found to be decreased in CF airways [3]. Furthermore, SNOs have been shown to increase expression, maturation and function of both wild-type and Δ F508 CFTR. [2325] Of interest, cysteine, which contains a thiol group, is the rate limiting amino acid in the synthesis of glutathione (GSH), [26] an antioxidant which contributes to the redox imbalance in CF. The low cysteine plasma concentrations seen in the CF patients studied here, may therefore not only contribute to low SNOs but also reduced GSH formation and consequently GSNO deficiency in CF.

Low L-arginine concentrations may, however, not only result in decreased NO or SNO formation but also in increased reactive oxygen nitrogen species that contribute to tissue damage. Although superoxide generation from NOS3 appears to be regulated by BH4 rather than L-arginine, [27] it is known that calmodulin-bound NOS can release reactive oxygen species such as superoxide and H2O2 at non-saturating L-arginine levels, [28, 29] and that NOS can generate NO and superoxide at the same time at low-saturating L-arginine levels. [30, 31] These products may react to generate peroxynitrite, and subsequently result in tyrosine nitration. In fact, nitrotyrosine has been found to be increased in CF lung tissue, [32] sputum, [33] and exhaled breath condensate from CF patients. [34]

Our data suggest that L-arginine deficiency in CF patients results from increased L-arginine consumption by arginase. The product of arginase activity, L-ornithine, is a precursor for the formation of polyamines (e.g., putrescine, spermidine, and spermine) and proline, which control cell proliferation and collagen production, respectively. [35] Polyamines may be particularly important in the lung because respiratory epithelial cells have a potent polyamine uptake system. [36] In addition, the polyamine spermine has been shown to down-regulate NO synthesis and cellular L-arginine transport by suppressing the expression of NOS2 and CAT-2B in alveolar macrophages. [37] Of interest, polyamine plasma levels have been reported to be increased in CF in an age-dependent manner. [38]

This is the first study to show that arginase I concentrations are increased in blood of CF patients with pulmonary exacerbation. Increased circulating arginase levels may explain why mean plasma L-arginine concentrations were decreased at this time point while arginase down-stream products were either normal (L-ornithine and proline) or increased (glutamic acid). It could also be argued that the initial decrease of several non-related amino acids followed by normalization during therapy may reflect an unspecific effect such as catabolic state related to infection or inflammation. However, the increase of L-ornithine and proline after antibiotic therapy in the face of normalized plasma L-arginine and arginase I levels provide evidence that arginase activity persists in compartments of these patients which are not reflected in measuring arginase in plasma. Evidence for increased arginase activity in clinically stable CF patients came also from a previous study showing a higher increase in plasma L-ornithine after a single dose of oral L-arginine in CF patients compared to healthy controls. [13]

Arginase I is usually located intracellular with high concentrations in erythrocytes and liver cells. We could recently demonstrate that the activity of arginase was high in CF sputum and, although decreasing with antibiotic treatment, remained significantly increased (approx. 10-fold) when compared to induced sputum from healthy controls. [9] Thus, increased plasma concentrations of arginase down-stream products (L-ornithine, proline, and glutamic acid) in the present of normal plasma arginase I levels could be explained by a "spill-over effect" of these metabolites from the CF airways into the blood stream. This mechanism may also explain the origin of increased plasma arginase I levels in the patients. Other sources of arginase activity could be tissues expressing arginase II or bacteria such as P. aeruginosa, but these were not detectable by the human arginase I ELISA used in this study.

Increased systemic arginase activity and decreased L-arginine bioavailability has recently also been found to be involved in the pathophysiology of sickle cell disease and asthma. [39, 40]. In sickle cell disease hemolysis-related release of erythrocyte arginase was significantly correlated with severity of pulmonary hypertension and increased mortality. [40] Animal experiments in a rodent model of allergic asthma suggest that increased arginase results in reduced L-arginine availability to constitutive NOS and thereby contributes to airway obstruction. [41, 42] In line with these experiment, increased arginase and decreased L-arginine bioavailability has been found in asthma patients. [39, 43] These observations suggest that L-arginine deficiency from increased arginase activity is not unique to CF but may play an important role in the pathogenesis of disease conditions with increased smooth muscle contractility.

Conclusion

These data provide evidence that the availability of L-arginine is reduced in patients with CF. In addition, high arginase concentrations in the blood in CF patients with pulmonary exacerbation results in systemic L-arginine deficiency and may thereby contribute to CF pathophysiology.

Declarations

Acknowledgements

The authors wish to thank M. Groch and B. Cirkel for excellent technical assistance.

Authors’ Affiliations

(1)
Children's Hospital, University of Duisburg-Essen
(2)
The Hospital for Sick Children, University of Toronto
(3)
Institute for Pharmacology and Toxicology, University of Bonn

References

  1. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004, 84:731–765.View ArticlePubMedGoogle Scholar
  2. Grasemann H, Michler E, Wallot M, Ratjen F: Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997, 24:173–177.View ArticlePubMedGoogle Scholar
  3. Grasemann H, Gaston B, Fang K, Paul K, Ratjen F: Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. J Pediatr 1999, 135:770–772.View ArticlePubMedGoogle Scholar
  4. Elphick HE, Demoncheaux EA, Ritson S, Higenbottam TW, Everard ML: Exhaled nitric oxide is reduced in infants with cystic fibrosis. Thorax 2001, 56:151–152.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Meng QH, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, Gruenert DC, Gyi KM, Hodson ME, Yacoub MH, Polak JM: Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998, 184:323–331.View ArticlePubMedGoogle Scholar
  6. Mhanna MJ, Ferkol T, Martin RJ, Dreshaj IA, van Heeckeren AM, Kelley TJ, Haxhiu MA: Nitric oxide deficiency contributes to impairment of airway relaxation in cystic fibrosis mice. Am J Respir Cell Mol Biol 2001, 24:621–626.View ArticlePubMedGoogle Scholar
  7. Grasemann H, Knauer N, Büscher R, Hübner K, Drazen JM, Ratjen F: Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 2000, 162:2172–2176.View ArticlePubMedGoogle Scholar
  8. Texereau J, Marullo S, Hubert D, Coste J, Dusser DJ, Dall'Ava-Santucci J, Dinh-Xuan AT: Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis. Thorax 2004, 59:156–158.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Grasemann H, Schwiertz R, Matthiesen S, Racke K, Ratjen F: Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005, 172:1523–1528.View ArticlePubMedGoogle Scholar
  10. Hey C, Boucher JL, Vadon-Le Goff S, Ketterer G, Wessler I, Racke K: Inhibition of arginase in rat and rabbit alveolar macrophages by N omega-hydroxy-D, L-indospicine, effects on L-arginine utilization by nitric oxide synthase. Br J Pharmacol 1997, 121:395–400.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Mori M, Gotoh T: Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 2000, 275:715–719.View ArticlePubMedGoogle Scholar
  12. Mori M, Gotoh T: Arginine metabolic enzymes, nitric oxide and infection. J Nutr 2004,134(Suppl 10):2820S-2825S.PubMedGoogle Scholar
  13. Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F: Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 2005, 25:62–68.View ArticlePubMedGoogle Scholar
  14. Liappis N, Gobien N, Schlebusch H: Reference values of fasting serum levels of free amino acids in children. Klin Padiatr 1990, 202:161–167.View ArticlePubMedGoogle Scholar
  15. Closs EI, Simon A, Vekony N, Rotmann A: Plasma membrane transporters for arginine. J Nutr 2004,134(Suppl 10):2752S-2759S.PubMedGoogle Scholar
  16. Bussiere FI, Chaturvedi R, Cheng Y, Gobert AP, Asim M, Blumberg DR, Xu H, Kim PY, Hacker A, Casero RA Jr, Wilson KT: Spermine causes loss of innate immune response to Helicobacter pylori by inhibition of inducible nitric-oxide synthase translation. J Biol Chem 2005, 280:2409–2412.View ArticlePubMedGoogle Scholar
  17. Ho LP, Innes JA, Greening AP: Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J 1998, 12:1290–1294.View ArticlePubMedGoogle Scholar
  18. Grasemann H, Kurtz F, Ratjen F: Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in cystic fibrosis patients. Am J Respir Crit Care Med, in press. 2006 Apr 20
  19. Gaston B, Singel D, Doctor A, Stamler JS: S-nitrosothiol signaling in respiratory biology. Am J Respir Crit Care Med 2006, 173:1186–1193.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Gaston B, Sears S, Woods J, Hunt J, Ponaman M, McMahon T, Stamler JS: Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet 1998, 351:1317–1319.View ArticlePubMedGoogle Scholar
  21. Que LG, Liu L, Yan Y, Whitehead GS, Gavett SH, Schwartz DA, Stamler JS: Protection from experimental asthma by an endogenous bronchodilator. Science 2005, 308:1618–1621.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Fang K, Johns R, Macdonald T, Kinter M, Gaston B: S-nitrosoglutathione breakdown prevents airway smooth muscle relaxation in the guinea pig. Am J Physiol Lung Cell Mol Physiol 2000, 279:L716-L721.PubMedGoogle Scholar
  23. Chen L, Patel RP, Teng X, Bosworth CA, Lancaster JR Jr, Matalon S: Mechanisms of cystic fibrosis transmembrane conductance regulator activation by s-nitrosoglutathione. J Biol Chem 2006, 281:9190–9199.View ArticlePubMedGoogle Scholar
  24. Howard M, Fischer H, Roux J, Santos BC, Gullans SR, Yancey PH, Welch WJ: Mammalian osmolytes and S-nitrosoglutathione promote Delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) protein maturation and function. J Biol Chem 2003, 278:35159–35167.View ArticlePubMedGoogle Scholar
  25. Andersson C, Gaston B, Roomans GM: S-Nitrosoglutathione induces functional DeltaF508-CFTR in airway epithelial cells. Biochem Biophys Res Commun 2002, 297:552–557.View ArticlePubMedGoogle Scholar
  26. Lyons J, Rauh-Pfeiffer A, Yu YM, Lu XM, Zurakowski D, Tompkins RG, Ajami AM, Young VR, Castillo L: Blood glutathione synthesis rates in healthy adults receiving a sulfur amino acid-free diet. Proc Natl Acad Sci USA 2000, 97:5071–5076.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Xia Y, Tsai AL, Berka V, Zweier JL: Superoxide generation from endothelial nitric-oxide synthase. A Ca 2+ /calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998, 273:25804–25808.View ArticlePubMedGoogle Scholar
  28. Stuehr D, Pou S, Rosen GM: Oxygen reduction by nitric-oxide synthases. J Biol Chem 2001, 276:14533–14536.View ArticlePubMedGoogle Scholar
  29. Heinzel B, John M, Klatt P, Bohme E, Mayer B: Ca 2+ /calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992, 281:627–630.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL: Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996, 93:6770–6774.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Stuehr DJ: Enzymes of the L-arginine to nitric oxide pathway. J Nutr 2004,134(Suppl 10):2748S-2751S.PubMedGoogle Scholar
  32. Morrissey BM, Schilling K, Weil JV, Silkoff PE, Rodman DM: Nitric oxide and protein nitration in the cystic fibrosis airway. Arch Biochem Biophys 2002, 406:33–39.View ArticlePubMedGoogle Scholar
  33. Jones KL, Hegab AH, Hillman BC, Simpson KL, Jinkins PA, Grisham MB, Owens MW, Sato E, Robbins RA: Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum. Pediatr Pulmonol 2000, 30:79–85.View ArticlePubMedGoogle Scholar
  34. Balint B, Kharitonov SA, Hanazawa T, Donnelly LE, Shah PL, Hodson ME, Barnes PJ: Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. Eur Respir J 2001, 17:1201–1207.View ArticlePubMedGoogle Scholar
  35. King NE, Rothenberg ME, Zimmermann N: Arginine in asthma and lung inflammation. J Nutr 2004,134(Suppl 10):2830S-2836S.PubMedGoogle Scholar
  36. Hoet PH, Nemery B: Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions. Am J Physiol Lung Cell Mol Physiol 2000, 278:L417-L433.PubMedGoogle Scholar
  37. Mossner J, Hammermann R, Racke K: Concomitant down-regulation of L-arginine transport and nitric oxide (NO) synthesis in rat alveolar macrophages by the polyamine spermine. Pulm Pharmacol Ther 2001, 14:297–305.View ArticlePubMedGoogle Scholar
  38. Baylin SB, Rosenstein BJ, Marton LJ, Lockwood DH: Age-related abnormalities of circulating polyamines and diamine oxidase activity in cystic fibrosis heterozygotes and homozygotes. Pediatr Res 1980, 14:921–925.View ArticlePubMedGoogle Scholar
  39. Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA, Morris SM Jr: Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 2004, 170:148–153.View ArticlePubMedGoogle Scholar
  40. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT: Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005, 294:81–90.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Meurs H, McKay S, Maarsingh H, Hamer MA, Macic L, Molendijk N, Zaagsma J: Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br J Pharmacol 2002, 136:391–398.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Maarsingh H, Tio MA, Zaagsma J, Meurs H: Arginase attenuates inhibitory nonadrenergic noncholinergic nerve-induced nitric oxide generation and airway smooth muscle relaxation. Respir Res 2005, 6:23.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM, Muntel EE, Witte DP, Pegg AA, Foster PS, Hamid Q, Rothenberg ME: Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003, 111:1863–1874.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Grasemann et al. 2006

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement